Biotech Values

[DewDiligence]

Oppenheimer MS survey:

73% of neurologists thought use of Copaxone could decrease. On average, Copaxone use could decline by 18.6% if gilenia is approved.

Is the 18.6% figure the average of all of the surveyed neurologists or the average of the 73% who think Gilenia will have an impact?

They estimate Teva's 2011 EPS could drop 6.5% if gilenia is approved.

It will drop much more than that if the FDA approves generic Copaxone :- )